Skip to main content
Article thumbnail
Location of Repository

Two-Dimensional Electrophoresis of Tau Mutants Reveals Specific Phosphorylation Pattern Likely Linked to Early Tau Conformational Changes

By Alexis Bretteville, Kunie Ando, Antoine Ghestem, Anne Loyens, Séverine Bégard, Jean-Claude Beauvillain, Nicolas Sergeant, Malika Hamdane and Luc Buée


The role of Tau phosphorylation in neurofibrillary degeneration linked to Alzheimer's disease remains to be established. While transgenic mice based on FTDP-17 Tau mutations recapitulate hallmarks of neurofibrillary degeneration, cell models could be helpful for exploratory studies on molecular mechanisms underlying Tau pathology. Here, “human neuronal cell lines” overexpressing Wild Type or mutated Tau were established. Two-dimensional electrophoresis highlights that mutated Tau displayed a specific phosphorylation pattern, which occurs in parallel to the formation of Tau clusters as visualized by electron microscopy. In fact, this pattern is also displayed before Tau pathology onset in a well established mouse model relevant to Tau aggregation in Alzheimer's disease. This study suggests first that pathological Tau mutations may change the distribution of phosphate groups. Secondly, it is possible that this molecular event could be one of the first Tau modifications in the neurofibrillary degenerative process, as this phenomenon appears prior to Tau pathology in an in vivo model and is linked to early steps of Tau nucleation in Tau mutants cell lines. Such cell lines consist in suitable and evolving models to investigate additional factors involved in molecular pathways leading to whole Tau aggregation

Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2002). Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein.
  2. (1996). AD2, a phosphorylation-dependent monoclonal antibody directed against tau proteins found in Alzheimer’s disease.
  3. (2006). Alzheimer’s disease and frontotemporal dementia: prospects of a tailored therapy?
  4. (2006). Alzheimer’s disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits.
  5. (1979). Anomalous electrophoretic mobility of Drosophila phosphorylated H1 histone: is it related to the compaction of satellite DNA into heterochromatin?
  6. (2005). Changed conformation of mutant Tau-P301L underlies the moribund tauopathy, absent in progressive, nonlethal axonopathy of Tau-4R/2N transgenic mice.
  7. (2001). Dysregulation of human brain microtubule-associated tau mRNA maturation in myotonic dystrophy type 1.
  8. (2002). Formation of aberrant phosphotau fibrillar polymers in neural cultured cells.
  9. (2002). Functional characterization of FTDP-17 tau gene mutations through their effects on Xenopus oocyte maturation.
  10. (2006). Improved long-term potentiation and memory in young tau-P301L transgenic mice before onset of hyperphosphorylation and tauopathy.
  11. (2006). Inducible expression of Tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs.
  12. (2003). Mitoticlike tau phosphorylation by p25-Cdk5 kinase complex.
  13. (2000). Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein.
  14. (2005). p25/Cdk5-mediated retinoblastoma phosphorylation is an early event in neuronal cell death.
  15. (2006). Pin1 allows for differential Tau dephosphorylation in neuronal cells.
  16. (2000). Rapid tau protein dephosphorylation and differential rephosphorylation during cardiac arrest-induced cerebral ischemia and reperfusion.
  17. (2005). Recent advances in experimental modeling of the assembly of tau filaments.
  18. (2006). Removal of Pattern-breaking Sequences in Microtubule Binding Repeats Produces Instantaneous Tau Aggregation and Toxicity.
  19. (2002). Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer’s disease.
  20. (2003). Stabletau overexpression in human neuroblastoma cells: an open door for explaining neuronal death in tauopathies.
  21. (2002). Tau assembly in inducible transfectants expressing wild-type or FTDP-17 tau.
  22. (2005). Tau suppression in a neurodegenerative mouse model improves memory function.
  23. (1902). Tau; pSer396-pS404 1:20 000* [14] M19G Rabbit Tau; human specific 1:20 000* [14] TauCter
  24. (2002). The complex relationship between soluble and insoluble tau in tauopathies revealed by efficient dephosphorylation and specific antibodies.
  25. (2000). The FTDP-17-linked mutation R406W abolishes the interaction of phosphorylated tau with microtubules.
  26. (1984). The purification of tau protein and the occurrence of two phosphorylation states of tau in brain.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.